|
1
|
Baracos VE, Martin L, Korc M, Guttridge DC
and Fearon KCH: Cancer-associated cachexia. Nat Rev Dis Primers.
4:171052018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fearon K, Strasser F, Anker SD, Bosaeus I,
Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N,
Mantovani G, et al: Definition and classification of cancer
cachexia: An international consensus. Lancet Oncol. 12:489–495.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Argiles JM, Busquets S, Stemmler B and
Lopez-Soriano FJ: Cancer cachexia: Understanding the molecular
basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Daly LE, Ní Bhuachalla ÉB, Power DG,
Cushen SJ, James K and Ryan AM: Loss of skeletal muscle during
systemic chemotherapy is prognostic of poor survival in patients
with foregut cancer. J Cachexia Sarcopenia Muscle. 9:315–325. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fearon K, Arends J and Baracos V:
Understanding the mechanisms and treatment options in cancer
cachexia. Nat Rev Clin Oncol. 10:90–99. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang QJ, Zhao JR, Hao J, Li B, Huo Y, Han
YL, Wan LL, Li J, Huang J, Lu J, et al: Serum and urine
metabolomics study reveals a distinct diagnostic model for cancer
cachexia. J Cachexia Sarcopenia Muscle. 9:71–85. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Quanjun Y, Genjin Y, Lili W, Bin L, Jin L,
Qi Y, Yan L, Yonglong H, Cheng G and Junping Z: Serum metabolic
profiles reveal the effect of formoterol on cachexia in
tumor-bearing mice. Mol Biosyst. 9:3015–3025. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen T, Li B, Xu Y, Meng S, Wang Y and
Jiang Y: Luteolin reduces cancerinduced skeletal and cardiac muscle
atrophy in a Lewis lung cancer mouse model. Oncol Rep.
40:1129–1137. 2018.PubMed/NCBI
|
|
9
|
Chen X, Wu Y, Yang T, Wei M, Wang Y, Deng
X, Shen C, Li W, Zhang H, Xu W, et al: Salidroside alleviates
cachexia symptoms in mouse models of cancer cachexia via activating
mTOR signalling. J Cachexia Sarcopenia Muscle. 7:225–232. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Argiles JM: The 2015 ESPEN Sir david
cuthbertson lecture: Inflammation as the driving force of muscle
wasting in cancer. Clin Nutr. 36:798–803. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lecker SH, Jagoe RT, Gilbert A, Gomes M,
Baracos V, Bailey J, Price SR, Mitch WE and Goldberg AL: Multiple
types of skeletal muscle atrophy involve a common program of
changes in gene expression. FASEB J. 18:39–51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Crossland H, Constantin-Teodosiu D,
Gardiner SM, Constantin D and Greenhaff PL: A potential role for
Akt/FOXO signalling in both protein loss and the impairment of
muscle carbohydrate oxidation during sepsis in rodent skeletal
muscle. J Physiol. 586:5589–5600. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bodine SC, Latres E, Baumhueter S, Lai VK,
Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K,
et al: Identification of ubiquitin ligases required for skeletal
muscle atrophy. Science. 294:1704–1708. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Glass DJ: Signaling pathways perturbing
muscle mass. Curr Opin Clin Nutr Metab Care. 13:225–229. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bodine SC, Stitt TN, Gonzalez M, Kline WO,
Stover GL, Bauerlein R, Zlotchenko E, Scrimgeour A, Lawrence JC,
Glass DJ and Yancopoulos GD: Akt/mTOR pathway is a crucial
regulator of skeletal muscle hypertrophy and can prevent muscle
atrophy in vivo. Nat Cell Biol. 3:1014–1019. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cai D, Frantz JD, Tawa NJ, Melendez PA, Oh
BC, Lidov HG, Hasselgren PO, Frontera WR, Lee J, Glass DJ and
Shoelson SE: IKKbeta/NF-kappaB activation causes severe muscle
wasting in mice. Cell. 119:285–298. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McFarlane C, Plummer E, Thomas M, Hennebry
A, Ashby M, Ling N, Smith H, Sharma M and Kambadur R: Myostatin
induces cachexia by activating the ubiquitin proteolytic system
through an NF-kappaB-independent, FoxO1-dependent mechanism. J Cell
Physiol. 209:501–514. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zimmers TA, Fishel ML and Bonetto A: STAT3
in the systemic inflammation of cancer cachexia. Semin Cell Dev
Biol. 54:28–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sandri M, Sandri C, Gilbert A, Skurk C,
Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH and Goldberg
AL: Foxo transcription factors induce the atrophy-related ubiquitin
ligase atrogin-1 and cause skeletal muscle atrophy. Cell.
117:399–412. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kitzmann M, Carnac G, Vandromme M, Primig
M, Lamb NJ and Fernandez A: The muscle regulatory factors MyoD and
myf-5 undergo distinct cell cycle-specific expression in muscle
cells. J Cell Biol. 142:1447–1459. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Long Y, Lin XT, Zeng KL and Zhang L:
Efficacy of intramuscular matrine in the treatment of chronic
hepatitis B. Hepatobiliary Pancreat Dis Int. 3:69–72.
2004.PubMed/NCBI
|
|
22
|
Li X, Wang X, Guo Y, Deng N, Zheng P, Xu
Q, Wu Y and Dai G: Regulation of endothelial nitric oxide synthase
and asymmetric dimethylarginine by matrine attenuates
isoproterenol-induced acute myocardial injury in rats. J Pharm
Pharmacol. 64:1107–1118. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Y, Wang B, Zhou C and Bi Y: Matrine
induces apoptosis in angiotensin II-stimulated hyperplasia of
cardiac fibroblasts: Effects on Bcl-2/Bax expression and caspase-3
activation. Basic Clin Pharmacol Toxicol. 101:1–8. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shao H, Yang B, HU R and Wang Y: Matrine
effectively inhibits the proliferation of breast cancer cells
through a mechanism related to the NF-κB signaling pathway. Oncol
Lett. 6:517–520. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang S, Cheng B, Li H, Xu W, Zhai B, Pan
S, Wang L, Liu M and Sun X: Matrine inhibits proliferation and
induces apoptosis of human colon cancer LoVo cells by inactivating
Akt pathway. Mol Biol Rep. 41:2101–2108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Q, Lai Y, Wang C, Xu G, He Z, Shang X,
Sun Y, Zhang F, Liu L and Huang H: Matrine inhibits the
proliferation, invasion and migration of castration-resistant
prostate cancer cells through regulation of the NF-κB signaling
pathway. Oncol Rep. 35:375–381. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bai S, Chen T, Yu X, Luo M, Chen X, Lin C,
Lai Y and Huang H: The specific killing effect of matrine on
castration-resistant prostate cancer cells by targeting the
Akt/FoxO3a signaling pathway. Oncol Rep. 37:2819–2828. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y, Wang S, Li Y, Xiao Z, Hu Z and
Zhang J: Sophocarpine and matrine inhibit the production of
TNF-alpha and IL-6 in murine macrophages and prevent
cachexia-related symptoms induced by colon26 adenocarcinoma in
mice. Int Immunopharmacol. 8:1767–1772. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Donohoe CL, Ryan AM and Reynolds JV:
Cancer cachexia: Mechanisms and clinical implications.
Gastroenterol Res Pract. 2011:6014342011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Muscaritoli M, Anker SD, Argiles J, Aversa
Z, Bauer JM, Biolo G, Boirie Y, Bosaeus I, Cederholm T, Costelli P,
et al: Consensus definition of sarcopenia, cachexia and
pre-cachexia: Joint document elaborated by Special Interest Groups
(SIG) ‘cachexia-anorexia in chronic wasting diseases’ and
‘nutrition in geriatrics’. Clin Nutr. 29:154–159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim H, Jang M, Park R, Jo D, Choi I, Choe
J, Oh WK and Park J: Conessine treatment reduces
dexamethasone-induced muscle atrophy by regulating MuRF1 and
atrogin-1 expression. J Microbiol Biotechnol. 28:520–526.
2018.PubMed/NCBI
|
|
32
|
Jackman RW, Floro J, Yoshimine R, Zitin B,
Eiampikul M, El-Jack K, Seto DN and Kandarian SC: Continuous
release of tumor-derived factors improves the modeling of cachexia
in muscle cell culture. Front Physiol. 8:7382017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xi QL, Zhang B, Jiang Y, Zhang HS, Meng
QY, Chen Y, Han YS, Zhuang QL, Han J, Wang HY, et al: Mitofusin-2
prevents skeletal muscle wasting in cancer cachexia. Oncol Lett.
12:4013–4020. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aulino P, Berardi E, Cardillo VM, Rizzuto
E, Perniconi B, Ramina C, Padula F, Spugnini EP, Baldi A, Faiola F,
et al: Molecular, cellular and physiological characterization of
the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC
Cancer. 10:3632010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang Q, Wan L, Zhou Z, Li Y, Yu Q, Liu L,
Li B and Guo C: Parthenolide from parthenium integrifolium reduces
tumor burden and alleviate cachexia symptoms in the murine CT-26
model of colorectal carcinoma. Phytomedicine. 20:992–998. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Neefjes ECW, van den Hurk RM,
Blauwhoff-Buskermolen S, van der Vorst MJDL, Becker-Commissaris A,
de van der Schueren MAE, Buffart LM and Verheul HMW: Muscle mass as
a target to reduce fatigue in patients with advanced cancer. J
Cachexia Sarcopenia Muscle. 8:623–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Carr RM, Enriquez-Hesles E, Olson RL,
Jatoi A, Doles J and Fernandez-Zapico ME: Epigenetics of
cancer-associated muscle catabolism. Epigenomics. Sep 25–2017.(Epub
ahead of print). doi: 10.2217/epi-2017-0058 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Haddad F, Zaldivar F, Cooper DM and Adams
GR: IL-6-induced skeletal muscle atrophy. J Appl Physiol (1985).
98:911–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Deans C and Wigmore SJ: Systemic
inflammation, cachexia and prognosis in patients with cancer. Curr
Opin Clin Nutr Metab Care. 8:265–269. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Patel HJ and Patel BM: TNF-α and cancer
cachexia: Molecular insights and clinical implications. Life Sci.
170:56–63. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Scheede-Bergdahl C, Watt HL, Trutschnigg
B, Kilgour RD, Haggarty A, Lucar E and Vigano A: Is IL-6 the best
pro-inflammatory biomarker of clinical outcomes of cancer cachexia?
Clin Nutr. 31:85–88. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fearon KC, Glass DJ and Guttridge DC:
Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell
Metab. 16:153–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang XY, Liang L, Chang JL, Yang MH and Li
ZG: Toxicity of matrine in Kunming mice. Nan Fang Yi Ke Da Xue Xue
Bao. 30:2154–2155. 2010.(In Chinese). PubMed/NCBI
|
|
45
|
Lu ZG, Li MH, Wang JS, Wei DD, Liu QW and
Kong LY: Developmental toxicity and neurotoxicity of two
matrine-type alkaloids, matrine and sophocarpine, in zebrafish
(Danio rerio) embryos/larvae. Reprod Toxicol. 47:33–41. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Burattini S, Ferri P, Battistelli M, Curci
R, Luchetti F and Falcieri E: C2C12 murine myoblasts as a model of
skeletal muscle development: Morpho-functional characterization.
Eur J Histochemistry. 48:223–233. 2004.
|
|
47
|
Clarke BA, Drujan D, Willis MS, Murphy LO,
Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E
and Glass DJ: The E3 Ligase MuRF1 degrades myosin heavy chain
protein in dexamethasone-treated skeletal muscle. Cell Metab.
6:376–385. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Castillero E, Alamdari N, Lecker SH and
Hasselgren PO: Suppression of atrogin-1 and MuRF1 prevents
dexamethasone-induced atrophy of cultured myotubes. Metabolism.
62:1495–1502. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Adams GR, Hather BM, Baldwin KM and Dudley
GA: Skeletal muscle myosin heavy chain composition and resistance
training. J Appl Physiol (1985). 74:911–915. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Desler MM, Jones SJ, Smith CW and Woods
TL: Effects of dexamethasone and anabolic agents on proliferation
and protein synthesis and degradation in C2C12 myogenic cells. J
Anim Sci. 74:1265–1273. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Schiaffino S, Dyar KA, Ciciliot S, Blaauw
B and Sandri M: Mechanisms regulating skeletal muscle growth and
atrophy. FEBS J. 280:4294–4314. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lokireddy S, McFarlane C, Ge X, Zhang H,
Sze SK, Sharma M and Kambadur R: Myostatin induces degradation of
sarcomeric proteins through a Smad3 signaling mechanism during
skeletal muscle wasting. Mol Endocrinol. 25:1936–1949. 2011.
View Article : Google Scholar : PubMed/NCBI
|
